Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival - PubMed (original) (raw)
Affiliations
- PMID: 16461304
Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival
Isabelle Vande Broek et al. Haematologica. 2006 Feb.
Erratum in
- Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle]
Abstract
Background and objectives: The capacity of multiple myeloma (MM) cells to home to and reside in the bone marrow implies that they must be equipped with appropriate adhesion molecules and chemokine receptors to allow transendothelial migration. We and others have previously shown that human MM cells express at least three different chemokine receptors that are functionally involved in MM cell migration, i.e. CCR1, CCR2 and CXCR4. In this study, we analyzed the surface expression of these chemokine receptors on primary MM cells from bone marrow samples.
Design and methods: Chemokine receptor expression was analyzed on bone marrow samples from a large population of patients (n=80) by flow cytometric analysis. The chemokine receptor expression profile was compared with clinical characteristics. Statistical significance was evaluated by Fisher's exact test. Survival curves were constructed using the Kaplan-Meier method. Cox regression analysis was used to determine the effect of chemokine receptor expression on survival.
Results: A heterogeneous expression pattern was observed for the three receptors tested. The chemokine receptor status (CRS) (i.e. no expression versus expression of at least one chemokine receptor), as well as expression of individual chemokine receptors was analyzed in relation to clinical and laboratory features and evaluated for prognostic significance. Chemokine receptor expression was significantly inversely correlated with disease activity: patients with active disease showed a significantly lower expression of CCR1, CCR2, as well as CXCR4 as compared to patients with non-active disease. Furthermore, the chemokine receptor expression profile correlated with serum beta2-microglobulin, C-reactive protein and hemoglobin. CRS, and the individual expressions of CCR1, CCR2 and CXCR4 in diagnostic bone marrow samples (n=70) correlated with survival. Multivariate analysis, using the Cox proportional hazard regression model, identified CRS, along with serum beta-microglobulin, as an independent prognostic factor.
Interpretation and conclusions: This study indicates that the chemokine receptor expression profile of MM cells correlates with disease status and survival of MM patients. This observation might reflect impaired chemoattraction and retention of MM cells within the bone marrow microenvironment, resulting in disease progression.
Comment in
- Chemokine receptor expression in multiple myeloma.
Sezer O. Sezer O. Haematologica. 2006 Feb;91(2):148a. Haematologica. 2006. PMID: 16461294 No abstract available.
Similar articles
- Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.
Trentin L, Miorin M, Facco M, Baesso I, Carraro S, Cabrelle A, Maschio N, Bortoli M, Binotto G, Piazza F, Adami F, Zambello R, Agostini C, Semenzato G. Trentin L, et al. Br J Haematol. 2007 Sep;138(5):594-602. doi: 10.1111/j.1365-2141.2007.06686.x. Br J Haematol. 2007. PMID: 17686053 - Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. Kaifi JT, et al. J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7. doi: 10.1093/jnci/dji431. J Natl Cancer Inst. 2005. PMID: 16368946 - Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma.
Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Laverdiere C, et al. Clin Cancer Res. 2005 Apr 1;11(7):2561-7. doi: 10.1158/1078-0432.CCR-04-1089. Clin Cancer Res. 2005. PMID: 15814634 - A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM. Lauta VM. Cancer. 2003 May 15;97(10):2440-52. doi: 10.1002/cncr.11072. Cancer. 2003. PMID: 12733143 Review. - The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.
Burger JA, Bürkle A. Burger JA, et al. Br J Haematol. 2007 May;137(4):288-96. doi: 10.1111/j.1365-2141.2007.06590.x. Br J Haematol. 2007. PMID: 17456052 Review.
Cited by
- Doxorubicin-loaded PEG-CdTe QDs conjugated with anti-CXCR4 mAbs: a novel delivery system for extramedullary multiple myeloma treatment.
Chen D, Chen F, Lu J, Wang L, Yao F, Xu H. Chen D, et al. J Mater Sci Mater Med. 2024 Jan 20;35(1):6. doi: 10.1007/s10856-023-06772-w. J Mater Sci Mater Med. 2024. PMID: 38244066 Free PMC article. - CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.
Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, Yan H, Tian Y, Wang Z, Yang Z, Yang S, Yang Y, Wang Q. Yang Y, et al. Int J Biol Sci. 2023 Jun 26;19(11):3341-3359. doi: 10.7150/ijbs.82317. eCollection 2023. Int J Biol Sci. 2023. PMID: 37497001 Free PMC article. Review. - [Update on biology of primary plasma cell leukemia].
Li Q, Sun CY, Hu Y. Li Q, et al. Zhonghua Xue Ye Xue Za Zhi. 2022 Jul 14;43(7):603-607. doi: 10.3760/cma.j.issn.0253-2727.2022.07.014. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709141 Free PMC article. Chinese. No abstract available. - The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
Yi Z, Ma T, Liu J, Tie W, Li Y, Bai J, Li L, Zhang L. Yi Z, et al. Front Immunol. 2022 Jul 25;13:925266. doi: 10.3389/fimmu.2022.925266. eCollection 2022. Front Immunol. 2022. PMID: 35958625 Free PMC article. Review. - Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Schwestermann J, et al. Front Oncol. 2022 May 26;12:899272. doi: 10.3389/fonc.2022.899272. eCollection 2022. Front Oncol. 2022. PMID: 35692781 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials